Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 10, 2006, Pages 1483-1493

  Lin, W A ^a   Tarn, Y H ^b   Tang, S L ^c  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG MECHANISM; GENOTYPE; HEPATITIS C; HUMAN; MEDICAL RECORD; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MARKOV CHAINS; MIDDLE AGED; RIBAVIRIN; TAIWAN;

EID: 33750455850     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03105.x     Document Type: Article

References (44)

1. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 341-4.
2. Suzuki K, Mizokami M, Cao K, et al. Prevalence of hepatitis C virus infection in Nanjing, southern China. Eur J Epidemiol 1997; 13: 511-5.
3. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
4. Wu CH, Lee MF, Kuo HS. Distribution of hepatitis C virus genotypes among blood donors in Taiwan. J Gastroenterol Hepatol 1997; 12: 625-8.
5. Sheu JC, Wang JT, Wang TH, et al. Prevalence of hepatitis C viral infection in a community in Taiwan. Detection by synthetic peptide-based assay and polymerase chain reaction. J Hepatol 1993; 17: 192-8.
6. Lin HH, Kao JH, Huang SC, Lee TY, Chen PJ, Chen DS. Prevalence, genotypes and antibody titer of hepatitis C virus in pregnant women in Taiwan. J Obstet Gynaecol 1995; 21: 557-62.
7. Chuang WL, Yu ML, Dai CY, Chang WY. Treatment of chronic hepatitis C in southern Taiwan. Intervirology 2006; 49: 99-106.
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
9. Saracco G, Olivero A, Ciancio A, et al. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Hepatology 2002; 36: 959-66.
10. Malone DC, Tran TT, Poordad FF. Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. J Manag Care Pharm 2005; 11: 687-94.
11. Grieve R, Roberts J, Wright M, et al. Cost-effectiveness of interferon alfa or peginterferon alfa with ribavirin for histologically mild chronic hepatitis C. Gut 2006; 55: 1332-8.
12. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. Pegylated interferon alfa-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: iii-iv, 1-125.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
14. Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 590-9.
15. Lee SD, Yu ML, Cheng PN, et al. Comparison of a 6-month course peginterferon alfa-2b plus ribavirin and interferon alfa-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005; 12: 283-91.
16. Lai MY. Combined interferon and ribavirin therapy for chronic hepatitis C in Taiwan. Intervirology 2006; 49: 91-5.
17. Yu ML, Dai CY, Lin ZY, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alfa-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int 2006; 26: 73-81.
18. Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg 2002; 65: 110-11.
19. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425-32.
20. Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993-9.
21. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687-94.
22. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.
23. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.
24. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-71.
25. Bruno S, Camma C, Di Marco V, et al. Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial. J Hepatol 2004; 41: 474-81.
26. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086-97.
27. Ikeda K, Kumada H, Saitoh S, et al. A randomized controlled trial of interferon-alfa in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus. J Hepatol 1998; 28: 910-1.
28. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351: 83-7.
29. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
30. Benckert C, Jonas S, Thelen A, et al. Liver transplantation for hepatocellular carcinoma in cirrhosis: prognostic parameters. Transplant Proc 2005; 37: 1693-4.
31. McHutchison JG, Ware JE Jr, Bayliss MS, et al. The effects of interferon alfa-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001; 34: 140-7.
32. Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 257-65.
33. McHutchison JG, Patel K. Future therapy of hepatitis C. Hepatology 2002; 36: S245-52.
34. Hadziyannis SJ. Why and how to treat chronic hepatitis C. Can J Gastroenterol 2000; 14 (Suppl. B): 45B-48B.
35. Wong JB, Poynard T, Ling MH, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol 2000; 95: 1524-30.
36. Koff RS. Cost-effectiveness of treatment for chronic hepatitis C. J Hepatol 1999; 31 (Suppl. 1): 255-8.
37. Patel K, McHutchison J. Peginterferon alfa-2b: a new approach to improving response in hepatitis C patients. Expert Opin Pharmacother 2001; 2: 1307-15.
38. De Filippi F, Colombo M. Treatment of chronic hepatitis C. J Biol Regul Homeost Agents 2003; 17: 133-7.
39. Colombo M, Rumi MG, Ninno ED. Treatment of chronic hepatitis C in Europe. J Hepatobiliary Pancreat Surg 2003; 10: 168-71.
40. Ishida H, Inoue Y, Wong JB, Okita K. Cost-effectiveness of ribavirin plus interferon alfa-2b for either interferon relapsers or non-responders in chronic hepatitis C: a Japanese trial. Hepatol Res 2004; 28: 125-36.
41. Arguedas M. Cost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. Pharmacoeconomics 2004; 22: 477-8, author reply 78-9.
42. Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/interferon alfa-2b after interferon relapse in chronic hepatitis C. Am J Med 2000; 108: 366-73.
43. Sinha M, Das A. Cost effectiveness analysis of different strategies of management of chronic hepatitis C infection in children. Pediatr Infect Dis J 2000; 19: 23-30.
44. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alfa 2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318-24.